JP2018524575A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018524575A5 JP2018524575A5 JP2017565057A JP2017565057A JP2018524575A5 JP 2018524575 A5 JP2018524575 A5 JP 2018524575A5 JP 2017565057 A JP2017565057 A JP 2017565057A JP 2017565057 A JP2017565057 A JP 2017565057A JP 2018524575 A5 JP2018524575 A5 JP 2018524575A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- disease
- citrullinated peptide
- chronic neurodegenerative
- mass spectrometry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562181665P | 2015-06-18 | 2015-06-18 | |
| US62/181,665 | 2015-06-18 | ||
| US201562233231P | 2015-09-25 | 2015-09-25 | |
| US62/233,231 | 2015-09-25 | ||
| US201562387149P | 2015-12-23 | 2015-12-23 | |
| US62/387,149 | 2015-12-23 | ||
| PCT/US2016/038439 WO2016205828A2 (en) | 2015-06-18 | 2016-06-20 | Role of citrullination in diagnosing diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018524575A JP2018524575A (ja) | 2018-08-30 |
| JP2018524575A5 true JP2018524575A5 (enExample) | 2019-07-25 |
Family
ID=57546510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017565057A Pending JP2018524575A (ja) | 2015-06-18 | 2016-06-20 | 疾患の診断におけるシトルリン化の役割 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11105817B2 (enExample) |
| EP (1) | EP3311176A4 (enExample) |
| JP (1) | JP2018524575A (enExample) |
| CN (1) | CN107923917A (enExample) |
| WO (1) | WO2016205828A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10309974B2 (en) | 2010-11-12 | 2019-06-04 | Cedars-Sinai Medical Center | Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease |
| EP3311176A4 (en) | 2015-06-18 | 2019-03-13 | Cedars-Sinai Medical Center | ROLE OF CITRULLINATION IN THE DIAGNOSIS OF ILLNESSES |
| US11988676B2 (en) | 2017-11-16 | 2024-05-21 | Brainbox Solutions, Inc. | Protein biomarker indicators of neurological injury and/or disease and methods of use thereof |
| EP4032969A4 (en) * | 2019-09-17 | 2023-08-16 | Kikkoman Corporation | METHOD FOR QUANTIFICATION OF CITRULLINE, OXIDOREDUCTASE FOR QUANTIFICATION, COMPOSITION FOR QUANTIFICATION, QUANTIFICATION KIT AND METHOD FOR EVALUATION OF PEPTIDYLARGININE DEIMINASE ACTIVITY |
| CN114839364B (zh) * | 2022-04-27 | 2025-09-12 | 珠海丽珠试剂股份有限公司 | 抗突变型瓜氨酸化波形蛋白抗体检测试剂盒及其应用 |
| EP4609859A1 (en) * | 2024-02-28 | 2025-09-03 | Universidad Pablo de Olavide | Inhibitors of the gene smpd1 for the treatment of spinal muscular atrophy |
| CN118001407B (zh) * | 2024-04-02 | 2024-06-21 | 北京大学人民医院 | Pad2在制备治疗缺血缺氧性恶性心律失常药物中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7537757B2 (en) | 1999-12-23 | 2009-05-26 | Childrens Hospital Los Angeles | Methods of facilitating vascular growth in cardiac muscle and methods for the production of recombinant EMAP II |
| DE10225574A1 (de) | 2002-06-10 | 2003-12-18 | Merck Patent Gmbh | Aryloxime |
| US20040265849A1 (en) | 2002-11-22 | 2004-12-30 | Applera Corporation | Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof |
| ES2314621T3 (es) | 2004-02-27 | 2009-03-16 | F. Hoffmann-La Roche Ag | Procedimiento de evaluacion de la artritis reumotoidea, mediante la medicion de anti-ccp y amiloide a serico. |
| US20070148704A1 (en) | 2005-10-06 | 2007-06-28 | Ursula Klause | Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis |
| JP5305259B2 (ja) * | 2007-12-25 | 2013-10-02 | 地方独立行政法人東京都健康長寿医療センター | 抗シトルリン化ｇｆａｐモノクローナル抗体及びその用途 |
| GB0803107D0 (en) | 2008-02-20 | 2008-03-26 | Axis Shield Diagnostics Ltd | Method |
| US9063148B2 (en) | 2008-10-22 | 2015-06-23 | The Henry M. Jackson Foundation For The Advancement Of Military Medicince, Inc. | Immunoassays for citrullinated proteins |
| JP5866206B2 (ja) | 2009-03-10 | 2016-02-17 | デューク ユニバーシティ | 冠動脈疾患および心血管イベントのリスクの予測 |
| CA2757444A1 (en) | 2009-03-30 | 2010-10-14 | Prometheus Laboratories Inc. | Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis |
| US10309974B2 (en) | 2010-11-12 | 2019-06-04 | Cedars-Sinai Medical Center | Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease |
| CA2817847C (en) | 2010-11-12 | 2018-02-13 | The Johns Hopkins University | Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease |
| GB201213012D0 (en) | 2012-07-23 | 2012-09-05 | Univ Warwick | Diagnostic for determining skelektal health |
| WO2014037911A1 (en) | 2012-09-10 | 2014-03-13 | Koninklijke Philips N.V. | System and method for estimating susceptibility to a medical condition |
| JP6365863B2 (ja) * | 2013-07-16 | 2018-08-01 | 国立大学法人 熊本大学 | 質量分析におけるペプチドピークの同定・定量のためのデータベース作成方法 |
| EP3311176A4 (en) | 2015-06-18 | 2019-03-13 | Cedars-Sinai Medical Center | ROLE OF CITRULLINATION IN THE DIAGNOSIS OF ILLNESSES |
-
2016
- 2016-06-20 EP EP16812648.0A patent/EP3311176A4/en not_active Withdrawn
- 2016-06-20 WO PCT/US2016/038439 patent/WO2016205828A2/en not_active Ceased
- 2016-06-20 US US15/575,697 patent/US11105817B2/en active Active
- 2016-06-20 CN CN201680044624.0A patent/CN107923917A/zh active Pending
- 2016-06-20 JP JP2017565057A patent/JP2018524575A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106574930B (zh) | 评价脑内的淀粉样蛋白β肽蓄积状态的替代性生物标记物和其分析方法 | |
| CN108027376B (zh) | 评价脑内的淀粉样蛋白β蓄积状态的多重生物标记物及其分析方法 | |
| EP2502999A3 (en) | Methods and compositions to treat and detect misfolded-SOD1 mediated diseases | |
| US20210109114A1 (en) | Diagnostic method for multiple sclerosis | |
| JP2021505844A5 (enExample) | ||
| JP2018500924A5 (enExample) | ||
| Simmons et al. | TSPO–PET imaging using [18F] PBR06 is a potential translatable biomarker for treatment response in Huntington’s disease: preclinical evidence with the p75NTR ligand LM11A-31 | |
| JP2010187674A5 (enExample) | ||
| JP2012530055A5 (enExample) | ||
| JP2012522754A5 (enExample) | ||
| JP2016524592A5 (enExample) | ||
| JP2009544284A5 (enExample) | ||
| JP2018534236A5 (enExample) | ||
| JP2018535921A5 (enExample) | ||
| JP2018516849A5 (enExample) | ||
| Zhao et al. | A fluorescent molecular imaging probe with selectivity for soluble tau aggregated protein | |
| WO2012149334A2 (en) | Methods and compositions for the generation and use of conformation-specific antibodies | |
| DE69830588D1 (de) | Diagnose und behandlung von krankheiten mittels anti-t-zell rezeptor-vbeta-antikörper oder peptide, an denen diese antikörper spezifisch binden, und esrp1 | |
| JP2025512827A (ja) | 抗体、融合タンパク質及びその使用 | |
| US20130171066A1 (en) | Polymeric complements to a b-amyloid peptides | |
| JP2007526759A5 (enExample) | ||
| JP2012513584A5 (enExample) | ||
| Levin et al. | Autoantibodies to heterogeneous nuclear ribonuclear protein A1 (hnRNPA1) cause altered ‘ribostasis’ and neurodegeneration; the legacy of HAM/TSP as a model of progressive multiple sclerosis | |
| JP2017007990A (ja) | アミロイド凝集性評価用汎用性量子ドットナノプローブ | |
| KR102328709B1 (ko) | 저분자 아밀로이드 베타 검출용 펩타이드 및 이의 용도 |